Brokers and banks usually stop taking bids earlier. Check the exact time with yours.
Total Issue Size
Fresh Issue + Offer For Sale
Fresh Issue (FI)
Proceeds go to the company
Offer For Sale (OFS)
Proceeds go to the existing investors
Establishment of R&D Facility
Setting up a dedicated research and development laboratory in Gujarat to advance formulation capabilities.
International Product Registrations
Funding dossier preparation and regulatory registration processes in targeted global export markets.
Marketing and Brand Promotion
Supporting participation in international pharmaceutical exhibitions, business outreach, and brand recognition.
Working Capital Requirements
Financing working capital needs to fund inventory holding and operating cycle expansion.
General Corporate Purposes
Meeting ongoing corporate needs and administrative contingencies.
(₹ in Crore)
Tap a bar to highlight a metric across periods and show its values.
Incorporated in 2021, Speciality Medicines Limited is a pharmaceutical enterprise engaged in the marketing, trading, and distribution of finished formulation products across specialized therapeutic segments including oncology, immunology, neurology, and rare diseases. The company operates through a dual commercial model combining contract manufacturing partnerships for international markets with targeted distribution of sourced specialty formulations in domestic and overseas channels, maintaining a portfolio spanning over 900 SKUs. Headquartered in India, Speciality Medicines Limited serves healthcare providers, hospital networks, and institutional distributors across more than 35 countries worldwide. Speciality Medicines focuses on expanding access to specialized therapies by working with manufacturing partners and distribution networks to meet the requirements of diverse healthcare markets. Its broad product portfolio and international presence support its growth strategy, while its emphasis on niche therapeutic segments enables it to serve evolving treatment needs across oncology, immunology, neurology and rare disease care.
No anchor investors added yet.
Source: RHP • Analysis provided for informational purposes
Last Updated: 21 October 2026, 1:06 AM
Specialized Therapeutic Focus
The company targets high-value niche therapeutic segments including oncology, immunology, and neurology with complex formulation requirements.
Comprehensive Product Portfolio
An extensive product catalog spans multiple delivery forms such as injectables, inhalers, tablets, and oral syrups.
Dual Commercial Model
Operations leverage third-party manufacturing partnerships for global exports alongside domestic sourcing and specialized distribution.
Broad International Distribution
Established distributor networks serve healthcare providers and hospital institutions across more than 35 countries.
Contract Manufacturing Dependency
The company relies on third-party manufacturing partners for product output, leaving it exposed to unexpected supply disruptions.
Customer Revenue Concentration
A significant share of annual revenue is concentrated among a limited group of major institutional buyers and overseas partners.
Strict Quality and Regulatory Compliance
Stringent regulatory specifications across diverse export jurisdictions create risks of shipment delays or order cancellations.
Speciality Medicines Limited
913, One World West, S. No. 396, FP 119, Village- Vejalpur, Ahmedabad, Gujarat, India - 380051
View on Maps →Skyline Financial Services Private Limited
No financial information whatsoever published anywhere, within this website, should be considered as an advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on information published on this website. The information on this website is based on information available as on date coupled with market perceptions.
You agree with the terms and conditions to use this website.
Grey-market disclaimer. GMP shown here is grey-market news only. We do not trade or deal in the grey market or subject-to rates, nor do we recommend trading in the grey market.
Not investment advice. IPO Nex is an information tool, not investment advice. We do not recommend buying or selling any securities. Always do your own research before applying to any IPO.
IPO Nex does not guarantee any listing gain or return. IPO investments are subject to market risks.
All times are IST.
© 2026 IPO Nex by Niota. All rights reserved.
Promoter Legal Proceedings
Outstanding legal matters involving promoter personnel could result in operational or management distractions.
Input Cost and Supply Chain Volatility
Fluctuations in raw material prices and international shipping freight charges may adversely impact operating margins.